Industry Insights

1. The Latest Techniques And Technology For Differentiating Capsids 6/24/2025

   Since AAV gene therapy’s origins, scientists and regulators have sought optimized ways to measure empty/full capsids. This expert reviews pros and cons of modern methods.

2. Advancing Gene Delivery: LNPs, Adenovirus, Lentivirus, And More 6/24/2025

   During this month’s Cell and Gene Live, Advancing Gene Delivery: LNPs, Adenovirus, Lentivirus, And More, expert panelists Francesca Barone, M.D., Ph.D., CSO at Candel Therapeutics and Karen Kozarsky, Ph.D., President of Vector BioPartners shared their perspectives on current challenges, technological innovations, and future directions in gene therapy vector development and application.

3. Hope For People With Spinocerebellar Ataxia 6/24/2025

   Spinocerebellar ataxia (SCA) is a rare, progressive, and fatal neurodegenerative disease with no approved treatments, but Biohaven Pharmaceuticals’ new drug troriluzole — designed to modulate glutamate and slow disease progression — has shown promise in clinical trials and is currently under FDA review, offering hope to patients and families facing this devastating disorder.

4. AI-Assisted QMS: Bridging ISO/IEC 42001:2023 And ICH Q10 For Pharmaceutical Excellence 6/23/2025

   Integrating AI into quality management systems (QMS) can be a transformative opportunity to enhance quality assurance, improve compliance, and enable proactive risk management. 

5. Navigating FDA Regulatory Changes: Policy Shifts, Deregulation, Restructuring, And Future Oversight 6/23/2025

   Recent shifts within the U.S. FDA reflect an increasingly complex tension between scientific rigor and accelerating political and economic pressures. Here are the newest developments and emerging focal points.

6. Rethinking Academic Translation In CGT: Inside The RISE Framework At Mass General Brigham 6/23/2025

   The RISE framework — focused on Resource sharing, Interdisciplinary collaboration, Sustainable funding, and Educational outreach — is helping academic medical centers such as Mass General Brigham overcome translational barriers in cell and gene therapy development and bring promising therapies closer to clinical application.

7. How Is RIM Software Transforming Regulatory Compliance? 6/20/2025

   Regulatory information management (RIM) software tools streamline global regulatory processes on a single cloud-based platform throughout the entire product life cycle.

8. EMA Guideline On Clinical-Stage ATMPs Comes Into Effect: On The Verge Of Convergence? 6/19/2025

   On July 1, 2025, the EMA’s Guideline on quality, non-clinical and clinical requirements for investigational advanced therapy medicinal products in clinical trials is slated to come into effect. 

9. Exploring The Market For Closed-Loop Cell Therapy Production 6/18/2025

   The second part of a discussion on closed-loop systems explores the CDMO and equipment landscape for scaling automated closed loop cell therapy manufacturing systems.

10. Closed-Loop Manufacturing Is The Cell Therapy Revolution We Need 6/18/2025

    In cell therapy manufacturing, automated closed systems with integrated software controls offer numerous benefits over traditional open systems.